Checking scan readings for solid cancer patients
Part of Cancer clinical trials.
This trial is checking how well radiologists (the doctors who read your scans) can measure tumors in patients with solid cancers. You will have your regular cancer scans, and the researchers will see if the scan-reading process runs smoothly. It's a study to improve how scan results are used in cancer care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a solid tumor cancer (not lymphoma or leukemia)
- Your tumors can be measured with scans using the RECIST 1.1 system
- You agree to participate and do not object to being in this study
- You are not allergic to contrast dye and do not have kidney problems that would prevent contrast use
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new X-ray system that looks at CT scans of the chest, belly, and pelvis. The goal is to see how well it works in real hospital use for adults.
This Phase 1 study tests whether an investigational PET scan tracer is safe and tolerable when used for PET imaging in people with certain solid cancers. It mainly looks at side effects and how well the scan can be done, not whether it treats cancer.
This trial tests a new type of PET scan (a special imaging test) called 89Zr-s-C1 to help detect and monitor solid tumors like melanoma, gastric cancer, or colorectal cancer. The scan may help doctors see tumors more clearly and track whether treatment is working.
This study tests whether a specialized nuclear imaging camera can better detect multiple tumors or lesions in your body. You'll receive a standard radioactive tracer scan (like a bone scan or thyroid scan) that's already part of your care, but we'll also image you with this newer camera technology to see if it works well.
This early-stage trial tests a new radioactive tracer called [68Ga]Ga-R54 that helps doctors see certain advanced cancers (like breast, lung, colon, ovary, pancreas, or multiple myeloma) on PET scans. The tracer targets a specific protein (CXCR4) found on cancer cells, which may help doctors better detect and understand your cancer.
This trial uses a special PET scan called theranostic PET to find and track tumors in people with cancer. It may help guide treatment decisions by showing where the cancer is and how active it is.
Hear when a new Solid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.